Clinical trials: Acquired Immunodeficiency Syndrome
HIV
Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance
Cystatin C, a protease inhibitor produced by most nucleated cells, is freely filtered by the kidneys, and its plasma assay reflects the GFR.
- Trial name
- HIVOL (NCT02522338)
- Testing
- iohexol
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
HIV Associate Weight Loss
Testosterone and Physical Function in HIV+ Men
Men infected with the HIV virus (the virus that causes AIDS) often lose weight even though they may try to eat more food to gain weight. The reasons for this weight loss are not clear.
- Trial name
- NCT00260143
- Testing
- Testosterone enanthate
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
This study will evaluate patient quality of life and tolerability of a HAART (highly active antiretroviral therapy) regimen containing twice-daily subcutaneous injections of Fuzeon in clinically stable, treatment-experienced…
- Trial name
- NCT00232908
- Testing
- ARV regimen, enfuvirtide [Fuzeon]
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Hazardous Drinking, Binge Drinking
A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention
This study will determine whether a group cognitive-behavioral therapy intervention that demonstrates preliminary evidence of reducing alcohol use among HIV-infected outpatients in western Kenya is effective when compared against…
- Conditions
- Hazardous Drinking, Binge Drinking, HIV-infected
- Trial name
- RAFIKI (NCT01503255)
- Testing
- cognitive behavioral group therapy, health education group
- Where
- Kenya
- Volunteers
- 614 people
- Sponsor
- Brown University
HIV Infections
A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications
The purpose of this study is to find out if it is safe for HIV-positive children who are responding well to their anti-HIV treatment to stop taking medications that prevent AIDS-related infections (opportunistic infections) such…
- Trial name
- NCT00001078
- Testing
- Hepatitis A Vaccine (Inactivated)
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
The "Thrive With Me" (TWM) trial is testing the efficacy of a mobile enhanced website aimed at improving Antiretroviral Therapy (ART) adherence for HIV-positive men who have sex with men (MSM).
- Trial name
- TWM (NCT02704208)
- Testing
- Thrive With Me Control, Thrive With Me Intervention
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- University of Minnesota
HIV Infections
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients.
- Trial name
- NCT00967187
- Testing
- bevirimat dimeglumine
- Where
- 4 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Myrexis Inc.
HIV
Rapid HIV Viral Load Monitoring in High Risk Patients In Uganda
The RAPID-VL study will take place in 20 HIV care health facilities in Southwestern Uganda. The study will test the hypothesis that a multi-component intervention package that targets barriers to efficient and timely HIV viral…
- Trial name
- RAPID-VL (NCT03553693)
- Testing
- RAPID-VL study intervention
- Where
- Uganda
- Volunteers
- 2,443 people
- Sponsor
- University of California, San Francisco
HIV Infections
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
The purpose of this study is to assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.
- Trial name
- NCT01435135
- Testing
- ALVAC-HIV, AIDSVAX B/E
- Where
- 2 sites in Thailand
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle…
- Trial name
- NCT00002414
- Testing
- CPI-1189
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Centaur Pharmaceuticals
HIV Infections
VENICE Study Nevirapine Full Dose/Dose Escalation
This study aims to compare the trough plasma concentrations of nevirapine after 7 days of treatment at the full dose from baseline with dose escalation in patients taking efavirenz who switch to nevirapine due to neuropsychiatric…
- Trial name
- VENICE (NCT00704249)
- Testing
- nevirapine
- Where
- 15 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Clinical Trial Agency of HIV Study Group
Human Immunodeficiency Virus, Alcohol-Related Disorders
Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa
The purpose of this study is to evaluate a stepped care behavioral intervention for HIV medication adherence and substance use ("Khanya") integrated into an HIV primary care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use, Substance Use
- Trial name
- NCT05933226
- Testing
- Khanya
- Where
- South Africa
- Volunteers
- 160 people
- Sponsor
- University of Maryland, College Park
HIV
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound, in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy for no less than 3 years and have a CD4+…
- Trial name
- Goldrake (NCT02176135)
- Testing
- Auranofin
- Where
- United States
- Sponsor
- Vaccine and Gene Therapy Institute, Florida
Metabolic Syndromes, HIV Infection
Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans
Kaohsiung Medical University Chung-Ho Memorial Hospital will provide a long-term free medical service in Indian Tibetans since July 2010.
- Trial name
- NCT01261221
- Where
- Taiwan
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Cardiovascular Disease, Alcohol Use Disorder
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health…
- Conditions
- Cardiovascular Disease, Alcohol Use Disorder, HIV Risk, Substance Use Disorders
- Trial name
- NCT05828849
- Testing
- Navigation, compensation, and personalization
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
HIV
TelePharm PrEP/PEP
In this study, the investigators will evaluate whether introducing a remote nurse to screen, counsel, and guide clients through HIV self-testing (via a telehealth platform) and support interested clients (via SMS) between…
- Trial name
- NCT07561658
- Testing
- Telehealth delivery of pharmacy PrEP/PEP, Standard pharmacy PrEP/PEP delivery
- Where
- Kenya
- Volunteers
- 1,580 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
This protocol represents the second in human study of TUTI-16, and is being conducted to continue to gather safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- THYMON-10001 (NCT01144026)
- Testing
- TUTI-16 (0.2mg), TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Thymon, LLC
HIV, ART
The SMART ART Study
The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with…
- Trial name
- NCT05090150
- Testing
- Home delivery of ART, Smart Lockers (Pele boxes), Best clinic practices + conditional lottery incentives
- Where
- South Africa
- Volunteers
- 874 people
- Sponsor
- Massachusetts General Hospital
HIV Prevention
Private-sector Access to Testing for Health Sustainability
New and innovative strategies are urgently needed to increase the uptake of HIV prevention and sexual and reproductive health services among adolescent girls and young women (AGYW) in sub-Saharan Africa.
- Trial name
- PATHS (NCT06820697)
- Testing
- Low HIVST kit subsidy, High HIVST kit subsidy
- Where
- Tanzania
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care
The goal of this clinical trial is to learn if the DSD model (SUSTAIN-DSD) is effective in improving participants HIV treatment adherence.
- Trial name
- NCT06554223
- Testing
- SUSTAIN-DSD, Enhanced (guideline-driven) Standard of Care (E-SoC)
- Where
- South Africa
- Volunteers
- 310 people
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.